BethKarlanMD

PubMed

• 3 citations
  Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
  Shalaka S. Hampras, Lara E. Sucheston-Campbell, Rikki Cannioto, Jenny Chang-Claude, Francesmary Modugno
  Oncotarget. 2016-07-05
• 1594 citations
  Pan-cancer analysis of whole genomes
  Peter J. Campbell, Gad Getz, Jan O. Korbel, Joshua M. Stuart, Jennifer L. Jennings
  Nature. 2020-02-06
• 24 citations
  Molecular similarities between primary peritoneal and primary ovarian carcinomas
  Lee-may Chen, S. D. Yamada, Y.-S. Fu, Rae Lynn Baldwin, Beth Y. Karlan
  International Journal of Gynecological Cancer. 2003-11-01

Journal Articles

• Association of p16 Expression with Prognosis Varies Across Ovarian Carcinoma Histotypes: An Ovarian Tumor Tissue Analysis Consortium Study  
  Robert P Edwards, Beth Y Karlan, Andrew Berchuck, The Journal of Pathology: Clinical Research
• Variants in Genes Encoding Small GTPases and Association with Epithelial Ovarian Cancer Susceptibility  
  Julie M Cunningham, Robert P Edwards, Elizabeth M Poole, Tanja Pejovic, Karen Lu, Kunle Odunsi, Beth Y Karlan, Christine S Walsh, Douglas A Levine, Andrew Berchuck, Da..., PLoS One
• Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast–Ovarian Cancer Susceptibility Locus  
  Susan M Domchek, Beth Y Karlan, Katherine L Nathanson, Kenneth Offit, Banu K Arun, Andrew Berchuck, Patricia A Ganz, Douglas A Levine, Nature
• Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: Results from a follow-up study  
  Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P,. . . Kalan B, . . . et al, Br J Cancer, 1/1/2014
• The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation  
  Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P,. . . Hereditary Breast Cancer Clinical Study Group (Karlan BY), Breast Cancer Res Treat, 1/1/2013
• International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers  
  Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, . . .Hereditary Breast Cancer Clinical Study Group (Karlan BY), Ann Surg Oncol, 1/1/2013
• Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation  
  Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P,. . . Karlan BY, . . . et al, Cllin Genet, 1/1/2013
• Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers  
  Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, . . . Karlan BY, . . . et al, Proc Natl Acad Sci USA, 1/1/2013
• Gynecologic Oncology: Update 2012  
  Karlan BY, Gynecologic Oncology, 1/1/2012
• The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers  
  Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, . . . Karlan BY, . . . et al, Br J Cancer, 1/1/2012
• The risk of breast cancer in women with a BRCA1 mutation from North America and Poland  
  Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, . . . Karlan BY, . . . et al, Int J Cancer, 1/1/2012
• Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations  
  Bordeleau L, Lipscombe L, Lubinski J. Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, . . . Karlan BY, . . . et al., Cancer, 1/1/2011
• Progress towards ovarian cancer early detection: Strategies, guidelines and clinical trials  
  Drescher CW, Karlan BY, The Female Patient, 1/1/2010
• Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer  
  Karam AK, Karlan BY, Gynecol Oncol, 1/1/2010
• Gynecologic Oncology Update 2010  
  Karlan BY, Gynecol Oncol, 1/1/2010
• Clinical implications of genetic testing for cancer susceptibility  
  Karlan BY, Lu KH, Mutch DG, ACOG Update, 1/1/2010
• Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations  
  Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N,. . . Karlan BY,. . . et al., J Natl Cancer Inst, 1/1/2010
• Fertility in women with BRCA mutations: a case-control study  
  Pal T, Keefe D, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. . . Karlan BY. . . et al, Fertil Steril, 1/1/2010
• BRCA1 and BRCA2 families and the risk of skin cancer  
  Ginsberg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group, Karlan BY,. . . et al., Familial Cancer, 1/1/2010
• Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update  
  Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, . . . Karlan BY, et al., Breast Cancer Res Treat, 1/1/2009
• Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers  
  Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, . . . Karlan BY, . . . et al., Gynecol Oncol, 1/1/2009
• ACOG Practice Bulletin: Hereditary Breast and Ovarian Cancer Syndrome  
  ACOG Committee on Practice Bulletins on Genetics and the Society of Gynecologic Oncologists with the editorial assistance of Beth Karlan, MD, Andrew Berchuck, MD and D..., Obstet Gynecol, 1/1/2009
• Debate: Routine screening for patients at high risk for ovarian cancer Pro: Patients at high risk for ovarian cancer should undergo routine screening  
  Karlan BY, Clin Ovarian Cancer, 1/1/2009
• ACOG Practice Bulletin: Hereditary Breast and Ovarian Cancer Syndrome  
  ACOG Committee on Practice Bulletins on Genetics and the Society of Gynecologic Oncologists with the editorial assistance of Beth Karlan, MD, Andrew Berchuck, MD and D..., Gynecol Oncol, 1/1/2009
• The devil is in the details  
  Karlan BY, Gynecol Oncol, 1/1/2008
• Join now to see all

Books/Book Chapters

• Gynecologic Oncology: Clinical Practice and Surgical Atlas 
  Karlan BYEditors: Karlan BY, Bristow RE, Li AJ.McGraw-Hill Publishers, New York, NY2012
• Surgery for Ovarian Cancer: Principles and Practice 
  Karlan BYEditors: Bristow RE, Karlan BY, Chi D.Taylor and Francis Publishing, United KingdomEdition 2nd,2010
• Surgery for Ovarian Cancer Principles and Practice 
  Chapter: Advanced Cytoreductive Surgery Program Development: Building a Cytoreductive Team 
  Page 291 - 299Zivanovic O, Chi DS, Karlan BYEditors: Bristow RE, Karlan BY and Chi DS.Taylor & Francis Publishers, United KingdomEdition 2nd,2010
• Surgery for Ovarian Cancer Principles and Practice 
  Chapter: Cytoreductive Surgery: Principles and Rationale. 
  Page 61 - 90Holschneider CH and Karlan BYEditors: Bristow RE, Karlan BY and Chi DS.Taylor & Francis Publishers, United KingdomEdition 2nd,2010
• Danforth's Obstetrics and Gynecology 
  Karlan BYEditors: Gibbs RS, Karlan BY, Haney A, Nygaard I.Lippincott Williams and Wilkins, Philadelphia, PAEdition 10th,2008
• Danforth's Obstetrics and Gynecology 
  Chapter: Ovarian and Tubal Cancers. 
  Cass I, Karlan BYEditors: Gibbs RS, Karlan BY, Haney A, Nygaard I.Lippincott Williams and Wilkins, Philadelphia, PA2008
• 5-Minute Ob/Gyn Consult 
  Chapter: Screening and well-woman care-ACOG guidelines. 
  Lang J, Karlan BYEditors: Hilard PJ, Hillard PJ.Lippincott, Williams and Wilkins, Philadelphia, PA2008
• 5-Minute Ob/Gyn Consult 
  Chapter: Cancer screening-Colorectal cancer. 
  Lang J, Karlan BYEditors: Hilard PJ, Hillard PJ.Lippincott, Williams and Wilkins, Philadelphia, PA2008
• Obstetric and Gynecology Clinics of North America 
  Chapter: Hereditary syndromes and ovarian cancer. 
  Pavelka J, Li AJ, , Karlan BYEditors: Carolyn Y. Muller.W. B. Saunders Company2007
• Surgery for Ovarian Cancer: Principles and Practice 
  Karlan BYEditors: Bristow RE, Karlan BY.Taylor and Francis Publishing, United Kingdom2006
• Surgery for Ovarian Cancer Principles and Practice 
  Chapter: Second-look Surgery. 
  Cass I, Karlan BYEditors: Bristow RE and Karlan BY.Taylor & Francis Publishers, United Kingdom2006
• Cancer: Principles & Practice of Oncology 
  Chapter: Ovarian cancer, peritoneal carcinoma, and fallopian tube carcinoma. 
  Karlan BY, Markman MA, Eifel PAEditors: V.T. DeVita, S. Hellman, Rosenberg SA.Lippincott Williams & WilkinsEdition 7th,2005
• Danforth's Obstetrics and Gynecology 
  Karlan BYEditors: Scott J, Gibbs RS, Karlan B, Haney A.Lippincott Williams and Wilkins, Philadelphia, PAEdition 9th,2003
• Danforth's Obstetrics and Gynecology 
  Chapter: Neoplasms of the ovarian and fallopian tube. 
  Page 971 - 1006Cass I, Karlan BYEditors: James Scott, Ronald S. Gibbs, Beth Karlan, Arthur Haney.Lippincott Williams & WilkinsEdition 9th,2003
• Danforth's Obstetrics and Gynecology 
  Chapter: Gestational trophoblastic neoplasms. 
  Page 1019 - 1030Li AJ, Karlan BYEditors: James Scott, Ronald S. Gibbs, Beth Karlan, Arthur Haney.Lippincott Williams & WilkinsEdition 9th,2003
• Ovarian Cancer 6 
  Chapter: Socio-economics of ovarian cancer screening. 
  Page 199 - 208Urban N, McIntosh MW, Clarke L, Jacobs IJ, Karlan B, Anderson G, Drescher CEditors: Jacobs IJ, Shepherd JH, Oram DH, Blackett AD, Luesley DM, Berchuck A, Hudson CN.Oxford University Press, New York, NY2002
• Tumors of the Pelvis 
  Chapter: Molecular biology of gynecologic malignancies. 
  Cass I, Baldwin RL, Karlan BYEditors: B.Ch. Golematis, K.A. Dimopoulos.J Wiley and Son2002
• Contemporary Therapy in Obstetrics and Gynecology Issues and Controversies 
  Chapter: Screening for ovarian cancer. 
  Page 399 - 403Platt LD, Karlan BY, Greene N, Walla CAEditors: Platt LD, Karlan BY, Greene N, Walla CA.W.B. Saunders Company, Philadelphia, PA2002
• Operative Gynecology 
  Chapter: Ovarian cancer risk and prophylactic oophorectomy. 
  Chen LM, Karlan BYEditors: David M. Gershenson, Alan H. DeCherney, Stephen L. Curry, Linda Brubaker.W.B. Saunders CompanyEdition 2nd,2002
• The Genetic Basis of Common Diseases 
  Chapter: Reproductive organ cancer. 
  Scheuner M, Karlan BYEditors: Richard A King, Jerome I. Rotter, Arno G. Motulsky.Oxford University PressEdition 2nd,2002
• Ovarian Cancer 6 
  Chapter: Preclinical and Phase I clinical studies of combinations of chemotherapy with recombinant adenovirus containing the full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer. 
  Pegram MD, Konecny G, Buller R, Runnebaum I, Slamon DJ, Nielsen LL, Horowitz J, Karlan BY2002
• Danforth's Obstetrics and Gynecology 
  Chapter: Disorders of the uterine cervix. 
  Page 805 - 835Bristow RE, Karlan BYEditors: James R. Scott, Philip J. DiSaia.Lippincott-Raven PublishersEdition 8th,1999
• Adenoviral Vectors for Gene Therapy 
  Chapter: Opportunities for p53 tumor suppressor gene therapy in ovarian and other peritoneal cancers. 
  Page 293 - 301Nielsen LL, Pegram M, Karlan B, Elkas J, Horowitz JAEditors: S Prem.Landes Bioscience1999
• Gynecology for the Primary Care Physician 
  Chapter: Vulvar cancer. 
  Page 189 - 194Elkas JC, Karlan BYEditors: Stovall TG, Ling FW.Current Medicine Group, Philadelphia, PAEdition 1st,1999
• Gynecology for the Primary Care Physician 
  Chapter: Vaginal cancer. 
  Page 195 - 198Elkas JC, Karlan BYEditors: Stovall TG, Ling FW.Current Medicine Group, Philadelphia, PAEdition 1st,1999
• Join now to see all

Abstracts/Posters

• Morbidity of triplemodality therapy in the management of early stage cervical cancer.
  Park SK, Axtell AE, Hakimian B, Li A, Leuchter R, Karlan B, Rimel BJ, Walsh C, Cass I, Western Association of Gynecologic Oncologists Meeting, Truckee, CA, 6/25/2014
• A KRAS hotspot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: A potential triage tool for Lynch Syndrome evaluation.
  Cohen J, Wiedemeyer R, Karlan B, Walsh C, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Genomic characterization of grade 3 endometrial carcinoma.
  Cohen J, Goodman M, Karlan B and Walsh C, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Lack of genomic predictors of recurrence in uterine carcinoma.
  Cohen J, Goodman M, Karlan B, Walsh C, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Risk factors for recurrent high grade vaginal intraepithelial lneoplasia and progression to carcinoma.
  Cohen J, Mehta S, Rimel BJ, Walsh C, Li A, Karlan B, Cass I, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• A novel clinical trial recruitment strategy for women's cancers.
  Rimel BJ, Lester J, Dang C, Sabacan L, Park D and Karlan B, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Too much too late aggressive measures and the timing of end-of-life care discussions in women with gynecologic malignancies.
  Zakhour M, Labrant L, Rimel BJ, Walsh C, Li A, Karlan B, Cass I, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Breast cancer following ovarian cancer in BRCA mutation carriers: What is the cost of surveillance?
  Paik D, Amersi F, Gangi A, Bresee C, Dang C, Karlan B, Li A, Walsh C, Rimel BJ, Leuchter R, Cass I, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Risk of breast cancer following ovarian cancer and the impact on overall survival.
  Paik D, Amersi F, Bresee C, Dang C, Gangi A, Karlan B, Li A, Walsh C, Rimel BJ, Leuchter R, Cass, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Impact of obesity on outcome of secondary cytoreductive surgery and overall survival in nwomen with recurrent ovarian cancer.
  Tran A, Rimel BJ, Walsh C, Cass I, Karlan B, Li, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• A novel online registry to improve clinical trial accrual.
  Rimel B, Dang C, Lester J, Sabacan L, Park D, Daneshvar C, Karlan B, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer.
  Herzog TJ, Richardson GE, Monk BJ, Karlan B, Marth C, Navale L, Warner DJ, Oza AM, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
• Non-serous ovarian carcinomas express low levels of ASS1: Implications for arginine depletions therapy.
  Cheon D-J, Bomalaski JS, Walts AE, Karlan BY, Orsulic S, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• Succlinate dehydrongenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism.
  Aspuria P-J, Lunt SY, Varemo L, Vargnes L, Reue K, Nielsen J, Karlan BY, Orsulic S, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• Breast cancer following ovarian cancer in BRCA mutation carriers: What is the cost of surveillance?
  Paik, D, Amersi F, Bresee C, Dang C, Karlan B, Li, A, Walsh C, Rimel BJ, Leuchter R, Cass I, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• The role of sphingosine kinase-1 in ovarian cancer progression and the tumor microenvironment.
  Beach JA, Aspuria P-J, Cheon J-J, Gozo MC, Karlan BY, Orsulic S, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• Mouse model of epithelial ovarian ncancer with define oncogenic drivers.
  Agadjanian H, Cheon D-J, Diaz E, Laury A, Miller C, Karlan B, Orsulic S, Walsh C, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• Gene expression profile in ovarian stroma of BRCA1 mutation carriers and age-matched BRCA1/2 wild type controls.
  Babkina N, Orsulic Li X, Gordon O, Karlan B, Cedars-Sinai Medical Center 5th Annual Research Day, Los Angeles, CA, 1/17/2014
• A phase 3, randomized, double-blind trial of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer: Trinova-1.
  Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, DelCampo JM, Ray-Coquard IR, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, ..., 18th International Meeting of the Europan Society of Gynaecological Oncology, Liverpool, UK, 10/19/2013
• Risk of diminished ovarian reserve in BRCA1/2 mutation carriers.
  Wang ET, Pisarska MD, Bresee C, Yii-Der MS, Chen I, Alexander C and Karlan BY, 69th Annual Meeting of the American Society of Reproductive Medicine, Boston, MA, 10/1/2013
• Too much, too late: Aggressive care in women with recurrent gynecologic malignancies and the timing of end-of-life discussions.
  LaBrant L, Rimel B, Walsh C, Li A, Karlan B, Cass I, Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, 6/1/2013
• What drives the development of synchronous endometrioid endometrial and ovarian cancers?
  Holzapfel M, Rimel B, Li A, Cass I, Karlan B, Walsh C, Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, 6/1/2013
• Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
  Cohen J, Tran A, Rimel B, Cass I, Walsh C, Karlan B, Li A, Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, 6/1/2013
• Obesity correlates with overall survival in women with recurrent epithelial ovarian cancer.
  Tran A, Rimel B, Walsh C, Cass I, Karlan B, Li A, Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, 6/1/2013
• Patterns of breast cancer surveillance and detection in women with serous ovarian/tubal or peritoneal carcinomas who have had BRCA mutation testing.
  Paik D, Amersi F, Gangi A, Dang C, Karlan B, Leuchter R, Li A, Walsh C, Rimel B, Cass I, Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, 6/1/2013
• Join now to see all

Lectures

• The prognostic significance of ADAM metallopeptidase domain 12 in advanced stage serous ovarian cancer. 
  Truckee, CA - 6/25/2014
• Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers. 
  Truckee, CA - 6/25/2014
• "The Mechanics of Writing and Publishing Great Papers: Perspecitive from the Editor-in-Chief of Gynecologic Oncology", Inaugural Lecturer 
  University of Alabama, Birmingham, AL - 11/15/2013
• "What is the Best Strategy to Reduce Ovarian Cancer Mortality?", Invited Professor 
  University of Alabama, Birmingham, AL - 11/14/2013
• "Translational Medicine in Gynecologic Oncology" Invited Professor 
  Fudan University Shanghai Cancer Center, Shanghai, China - 10/28/2013
• "How Can We Publish a Paper in Gynecologic Oncology and Specialists Training of Gynecological Oncology in the USA" Invited Featured Speaker 
  Nanjing, China - 10/26/2013
• "Translational Medicine in Gynecologic Oncology" Visiting Professor 
  Peking Union Medical College Hospital, Beijing, China - 10/23/2013
• "What is the Best Strategy to Reduce Ovarian Cancer Mortality?", Invited Speaker 
  Stanford, CA - 10/15/2013
• "My Role as an ACS Funded Clinical Professor and the Importance of Funding Young Investigators" 
  Los Angeles, CA - 5/21/2013
• "Video Shoot for ACS Campaign" 
  Los Angeles, CA - 5/11/2013
• "Women's Health-Everything But Cancer: Heart, Bowels and More" 
  Cedars-Sinai Board of Governors HealthCare College, Los Angeles, CA - 5/7/2013
• "Improving Cancer Outcomes in the Era of Limited Health Care Resources" 
  Beverly Hills, CA - 5/6/2013
• "The Mechanics of Manuscript Preparation: Lessons from the Editor-in Chief of Gynecologic Oncology" Invited Speaker 
  Los Angeles, CA - 3/8/2013
• "Winning the Next Chapter of our Lives" 
  Temple Emanual, Los Angeles, CA - 2/23/2013
• "Scientific Integrity and Publication Ethics" 
  Los Angeles, CA - 12/19/2012
• "Individualized Approaches to Ovarian Cancer" 
  Cedars-Sinai Medical Center, Los Angeles, CA - 10/26/2012
• "Personalized Approaches to Ovarian Cancer" Invited Speaker 
  New York, NY - 10/9/2012
• Grand Rounds: "Inherited Susceptibility to Ovarian Cancer: Clinical Implications and Challenges" Invited Speaker 
  Albert Einstein School of Medicine, New York, NY - 10/9/2012
• "Personalized Approaches to Ovarian Carcinoma" Invited Speaker 
  Kailua-Kona, HI - 9/7/2012
• "Individualized Approaches to Ovarian Cancer" Invited Speaker 
  MD Anderson Cancer Center, Houston, TX - 7/13/2012
• "What is the Origin of Serous Ovarian Carcinoma: Surface Epithelium vs. Distal Fallopian Tube" Invited Moderator 
  Chicago, IL - 4/1/2012
• Grand Rounds: "Personalized Approaches to Ovarian Cancer" Invited Speaker 
  UCSD, Department of Reproductive Medicine - 1/25/2012
• "Conversations About Cancer" 
  Los Angeles, CA - 1/1/2012
• "Abdominal Debulking of Gynecologic Malignancies: Rationale and Techniques" Co-Moderator 
  San Francisco, CA - 10/24/2011
• "Personalized Approaches to Ovarian Cancer" Invited Professor 
  Harvard, Boston, MA - 10/18/2011
• Join now to see all

Other

• "Interview for Lifescript.com" 
  Beth Young Karlan, MD
  1/1/2013
• "Interview for Studio 11" 
  Beth Young Karlan, MD
  1/1/2013
• CA-125: To monitor or not to monitor? 
  Rustin G, Karlan BY and Markman M
  http://www.medscape.com
  3/8/2012
• "Home and Family" 
  Beth Young Karlan, MD, Hallmark Cable Television Show
  1/1/2012
• "Vital Options International" 
  Beth Young Karlan, MD, Talk Radio
  1/1/2011
• "The Group Room" 
  Beth Young Karlan, MD, Cancer Talk Radio
  1/1/2009
• Documentary: "The Whisper-The Silent Crisis of Ovarian Cancer" 
  Beth Young Karlan, MD, PBS
  1/1/2009
• A preclinical mouse model for uterine leiomyosarcoma. 
  Ioffe YJM, Xing D, Aspuria P-J, Karlan B, Orsulic S, Electronic Update Sarcoma Newsletter
  1/1/2009
• Ovarian Cancer: Updates from the 16th International Meeting of the European Society of Gynaecological Oncology. 
  Coleman R, Karlan BY, European Society of Gynaecological Oncology Newsletter
  1/1/2009
• Satellite Media Tour, "Ovarian Cancer Awareness" 
  Beth Young Karlan, MD, Callaway Golf Foundation
  1/1/2008
• Satellite Media Tour, "Gynecologic Cancer Awareness" 
  Beth Young Karlan, MD, Gynecologic Cancer Foundation
  1/1/2008
• Genetic testing in the gynecology practice. 
  Wang J, Karlan BY, Women's Health, Gynecology Edition
  1/1/2003
• Management of patients who carry a cancer gene. 
  Wang J, Karlan BY, Women's Health, Gynecology Edition
  1/1/2003
• Ovarian cancer treatment options and symptom management. 
  Karlan BY, Coping
  5/1/2000
• Breast cancer prevention. 
  Li AJ, Karlan BY, OB/GYN Special Edition
  1/1/2000
• Join now to see all